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None of the licensing studies of dolutegravir (DTG) reported any treatment-emergent resistance among DTG-treated individuals, 
though virological failure in treatment-naïve and treatment-experienced, integrase strand transfer inhibitor (INSTI)–naïve indi-
viduals has been reported in clinical practice. While the spectrum of dolutegravir-selected mutations and their effects on clinical 
outcome have been described, the clinical characteristics of these rare but important virological failure cases are often overlooked. 
In this perspective piece, we focus on key clinical aspects of emergent resistance to DTG among treatment-naïve and treatment-
experienced INSTI-naïve patients, with an aim to inform clinical decision-making. Poor adherence and HIV disease factors con-
tribute to emergent drug resistance, even in regimens with high resistance barriers. Patients with severe immunosuppression or 
poor adherence are under-represented in licensing studies, and these patients may be at higher risk of treatment failure with DTG 
resistance, which requires close clinical and laboratory follow-up.
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Multiple international guidelines recom-
mend dolutegravir (DTG)-based antire-
troviral therapy as a preferred first- and 
second-line treatment regimen for HIV-1, a 
shift prompted by the efficacy, safety, and re-
sistance barrier of DTG. Although the spec-
trum of dolutegravir-selected mutations 
and their effects on clinical outcome have 
been described [1], the clinical characteris-
tics of rare but important virological failure 
cases are often overlooked. This perspective 
piece will particularly focus on key clin-
ical aspects of emergent resistance to DTG 
among treatment-naïve and treatment-
experienced integrase strand transfer inhib-
itor (INSTI)–naïve patients, with an aim to 
inform clinical decision-making.
TREATMENT-NAÏVE INDIVIDUALS
In total, we identified 5 VF cases 
(Table 1). In a retrospective cohort study 
of patients starting or switching to an 
INSTI-containing regimen, 1 VF case 
was described out of 58 patients starting 
DTG-based therapy; this person had vi-
rological rebound at 11  months after a 
period of viral suppression, associated 
with emergent T66I [2]. Although no 
pharmacokinetic (PK) data were avail-
able, poor adherence was reported. In 
the ACTG 5353 trial, 3 participants out 
of 120 on DTG and lamivudine (3TC) 
had VF [3]. One participant experienced 
viral rebound at week 8 after an initial re-
sponse at week 4, followed by prolonged 
viremia; M184V and R263R/K emerged 
at week 14. The virological rebound was 
linked to very poor adherence and pos-
sible intermittent monotherapy, with un-
detectable DTG levels.
In the remaining 3 case reports, DTG 
resistance is reported in patients with 
excellent reported medication adher-
ence, all of whom had advanced HIV 
disease and active co-infections. Fulcher 
et  al. reported a virological failure (VF) 
in a severely immunosuppressed patient 
with Pneumocystis jirocecii pneumonia 
(PCP) who was admitted to intensive care 
[4]. After a decline in HIV viral load (VL) 
to 2770 copies/mL at week 2, the VL in-
creased to 6510 copies/mL and then 15 700 
copies/mL at days 23 and 27, respectively, 
despite full adherence throughout the 
hospital stay. Deep sequencing of reverse 
transcriptase (RT) and integrase (IN) 
gene amino acid region 142–165 revealed 
M184V and a selection of I151V-G163E 
followed by the emergence of Q148R. The 
patient subsequently achieved virologic 
suppression on tenofovir alafenamide 
(AF)/emtricitabine/rilpivirine/DTG. 
Pena et al. [5] reported VF in a severely 
immunosuppressed patient diagnosed 
with HIV while in the hospital for spinal 
surgery subsequently complicated by 
Staphylococcus aureus infection requiring 
rifampicin. After an initial VL decline to 
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3461 copies/mL at week 4, VF was con-
firmed at week 12 with a VL of 126 393 
copies/mL. Deep sequencing revealed 
M184V at week 4, followed by R263K 
plus M184V and subsequent evolution of 
E157Q. Despite receiving 50 mg BD with 
concomitant rifampicin, DTG plasma 
levels were below the expected in vitro 
protein-adjusted 90% inhibitory concen-
tration  IC90 of 64  ng/mL at week 4.  The 
patient achieved virologic suppression on 
tenofovir DF, darunavir/cobicistat, and 
rilpivirine. Lubke et al. reported another 
VF in a severely immunosuppressed pa-
tient with disseminated tuberculosis [6]. 
Treatment included rifabutin, so DTG 
was dosed once daily. The patient had a 
3-log viral load decline in the first 3 weeks; 
however, postdischarge, they experienced 
viral rebound at week 8 and subsequently 
had persistent 103-copies/mL viremia. 
Deep sequencing revealed the evolution 
of R263K at week 8 and G118R by week 
15. Suboptimal DTG levels were recorded 
despite good reported adherence.
TREATMENT-EXPERIENCED INSTI-
NAÏVE PATIENTS
We Identified 10 VF Cases With Emergent DTG 
Resistance
Among 627 patients in the DAWNING 
trial, 312 patients were randomized to 
dolutegravir. Among those 2 with base-
line NRTI resistance mutations devel-
oped VF with INSTI resistance mutations 
(0.6%) (Table  1) [7]. Both had >100k 
viral load at the time of ART initiation, 
and VF was observed at weeks 48 and 36 
with G118R.
In the SAILING trial, of the 715 pa-
tients randomized, 5 individuals on 
dolutegravir developed VF with INSTI 
resistance mutation [8]. Two individ-
uals (0.6%) developed 1 or more INSTI 
resistance mutations by week 48. One 
patient had fluctuating HIV-RNA after 
week 4 despite being on DTG plus 
Tenofovir disoproxil fumarate (TDF) and 
darunavir/r and developed R263K substi-
tution. Another 3 (0.8%) patients devel-
oped mutations after week 48. Of those, 
2 had baseline VL >100k copies/mL. The 
first patient had a DTG trough level below 
the limit of detection at week 24 and ex-
perienced VF at week 108 with emergent 
N155H. The second patient had docu-
mented noncompliance and developed 
VF at week 72 with emergent N155H, 
I60L, and T97A. Both had a loss of 
M184V. The third patient had a baseline 
VL <1000 copies/mL, showed a gradual 
VL increase from week 96 to week 132, 
and developed emergent R263K.
In the IMPAACT P1093, heavily 
treated children aged 12–18 were given 
weight-based dolutegravir [9]. Of the in-
itial 23 recruited, 1 developed emergent 
INSTI resistance. A  subsequent analysis 
of 38 adolescents identified 2 additional 
cases of VF with emergent INSTI resist-
ance. All 3 cases had documented non-
compliance before developing VF [10].
In the Lepik et al. study, VF with emer-
gent INSTI resistance was observed 
in 2 patients. Both were on DTG with 
Lamivudine (3TC)  and abacavir (ABC) 
and had baseline CD4 counts >200; 1 
had HIV RNA <50, and the other had 
VL 1-100.000 copies/mL. Both had lower 
than optimum compliance and devel-
oped VF at week 38 and week 24 with 
emergent 263K [2].
DISCUSSION
We reviewed relatively rare but important 
cases of treatment failure with emergent 
DTG resistance. Clinically important risk 
factors for the development of resistance 
include poor medication adherence, drug 
interactions, and HIV disease factors, in 
particular, high baseline VL and active 
opportunistic infections.
Of the 15 cases, 10 had either subop-
timal DTG levels when they were meas-
ured or had documented poor adherence, 
and 3 had advanced HIV and severe ac-
tive infections. Factors such as malab-
sorption could influence the plasma PK 
of antiretrovirals (ARVs) in severely im-
munosuppressed HIV patients [11–13]. 
Drug absorption in critically ill patients 
may be impaired [14]. Administration 
of drugs through enteral feeding tubes St
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can decrease DTG drug absorption [15]. 
Although the efficacy of twice-daily DTG 
dosing with rifampicin and once-daily 
dosing with rifabutin is considered suffi-
cient [16, 17], drug interactions may play 
an important role. These observations 
highlight that critically ill individuals 
with concurrent AIDS-defining active 
infection or individuals with poor adher-
ence require closer follow-up.
In addition, 4 treatment-naïve and 5 
treatment-experienced patients had a 
baseline VL >100 000 copies/mL, which 
has been associated with treatment 
failure in some studies with INSTI-
based regimens [2, 18]. In GEMINI and 
NAMSAL [19, 20], CD4s <200 Cells/μL 
and VLs >100k copies/mL, respectively, 
had more virologic failure, whereas Lepik 
et  al. [9] demonstrated an association 
with emergence of resistance. The lack of 
viral load or genotypic testing, especially, 
may influence the proportion of persons 
with VF and emergent INSTI resistance 
in low- and middle-income countries.
These findings also have some impli-
cations for bictegravir (BIC)  use. Lozano 
et  al. described a VF case on bictegravir/
emtricitabine/tenofovir alafenamide in an 
INSTI-experienced patient with a long his-
tory of noncompliance [21]. After a period 
of loss to follow-up, this case presented 
with cerebral toxoplasmosis and a VL of >1 
million copies/mL and CD4 of 37 cells/mL. 
Although the VL dropped to 1084 copies/
mL following 4 weeks of bictegravir/
emtricitabine/tenofovir alafenamide, the 
patient developed PML, during which ART 
was given via an nasogastric (NG) tube for 
6 weeks. VF with VL of >10 000 copies/
mL was developed, with emergence of 
M184V and R263K. Two additional cases 
of virologic failure with resistance have 
been reported on bictegravir-based regi-
mens, 1 R263K and R138K selection after 
switching from TDF/FTC/elvitegravir/
cobicistat and another with the addition 
of A256V, a novel mutation in integrase 
gene (unpublished results).
Transmission of INSTI resistance mu-
tations of clinical significance remains a 
very rare event—in 1 recent series, it was 
found in 2/4631 individuals, and neither 
had DTG or BIC resistance [22].
In conclusion, poor adherence and 
HIV disease factors may contribute to 
emergent drug resistance, even in regi-
mens with high resistance barriers such 
as those including dolutegravir. Patients 
with severe immunosuppression or poor 
adherence are under-represented in li-
censing studies, and these patients may 
be at higher risk of treatment failure with 
DTG resistance, which requires close 
clinical and laboratory follow-up.
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